Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6269528 | 1.00 | KCNA5 (0.47) | KCNA5ABCB1KCNH2CYP1A2CYP2C9 | |
| SCHEMBL13476183 | 0.89 | KCNA5 (0.46) | KCNA5ABCB1KCNH2KMT2ANPC1 | |
| SCHEMBL13476265 | 0.88 | KCNA5 (0.45) | KCNA5ABCB1KCNH2NPC1RAB9A | |
| SCHEMBL13199606 | 0.88 | KCNA5 (0.45) | KCNA5ABCB1KCNH2KMT2ANPC1 | |
| SCHEMBL13476152 | 0.87 | KCNA5 (0.45) | KCNA5ABCB1KCNH2KMT2ANPC1 | |
| SCHEMBL13476266 | 0.87 | KCNH2 (0.45) | KCNA5ABCB1KCNH2CYP1A2CYP2C9 | |
| SCHEMBL13476169 | 0.87 | KCNA5 (0.46) | KCNA5ABCB1KCNH2KMT2ANPC1 | |
| SCHEMBL2882213 | 0.87 | NPC1 (0.48) | KCNA5ABCB1KCNH2KMT2ANPC1 | |
| SCHEMBL2882211 | 0.87 | NPC1 (0.48) | KCNA5ABCB1KCNH2KMT2ANPC1 | |
| SCHEMBL2876618 | 0.87 | NPC1 (0.48) | KCNA5ABCB1KCNH2KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248694-A1 | THERAPEUTIC AGENT FOR TREATING BRADYARRHYTHMIA | OSAKA UNIVERSITY (JP) | 2023-08-10 | — | — | US | disclosed |
| US-20230248694-A1 | THERAPEUTIC AGENT FOR TREATING BRADYARRHYTHMIA | OSAKA UNIVERSITY (JP) | 2023-08-10 | — | — | US | disclosed |
| CN-113543849-A | Therapeutic agent for hereditary bradyarrhythmia | 国立大学法人大阪大学 | 2021-10-22 | — | — | CN | disclosed |
| EP-1732929-B1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781483-B2 | Benzopyran compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-7041700-B2 | Substituted benzopyran derivatives against arrhythmia | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-05-09 | — | — | US | disclosed |
| US-20040152763-A1 | Substituted benzopyran derivatives against arrhythmia | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | KCNA5 101/4885ABCB1 647/4885KCNH2 28/4885 |
| US-20230248694-A1 | THERAPEUTIC AGENT FOR TREATING BRADYARRHYTHMIA | KCNH1, KCNN2, KCNN1 | KCNA5 67/4885ABCB1 164/4885KCNH2 6/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | KCNA5 67/4885ABCB1 580/4885KCNH2 21/4885 |
| US-20040152763-A1 | Substituted benzopyran derivatives against arrhythmia | CBR1, KCNH1, SCN8A | KCNA5 37/4885ABCB1 214/4885KCNH2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.